Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD)

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 29, Issue 6, 2016, Pages 855-862

  Chaiworapongsa, Tinnakorn ^a,b   Romero, Roberto ^a,c,d,e   Korzeniewski, Steven J ^a,b,d   Chaemsaithong, Piya ^a,b   Hernandez Andrade, Edgar ^a,b   Segars, James H ^a   Decherney, Alan H ^a   McCoy, M Cathleen ^f   Kim, Chong Jai ^a,g   Yeo, Lami ^a,b   Hassan, Sonia S ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f Winchester Medical Center   (United States)

^g University of Ulsan College of Medicine   (South Korea)

Author keywords

Angiogenic factors; Maternal floor infarction; Placental growth factor; Preeclampsia; Proton pump inhibitor; Soluble endoglin; Soluble vascular endothelial growth factor receptor 1

Indexed keywords

PRAVASTATIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; ECHOGRAPHY; FEMALE; FETUS; FETUS DEATH; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; LIVE BIRTH; MASSIVE PERIVILLOUS FIBRIN DEPOSITION OF THE PLACENTA; PLACENTA DISORDER; PREGNANT WOMAN; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; ABORTION, HABITUAL; ANIMAL; BLOOD; PLACENTA DISEASES; PREGNANCY;

ABORTION, HABITUAL; ADULT; ANIMALS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULINS, INTRAVENOUS; PLACENTA DISEASES; PRAVASTATIN; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84949604065     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2015.1022864     Document Type: Article

References (101)

1. Katzman PJ, Genest DR. Maternal floor infarction and massive perivillous fibrin deposition: histological definitions, association with intrauterine fetal growth restriction, and risk of recurrence. Pediatr Dev Pathol 2002;5:159-64.
2. Benirschke K, Driscoll S. The pathology of the human placenta. In: Henke-Lubarsch, ed. Handbook of pathology anatomy. Berlin Heidelberg: Springer-Verlag; 1967:500.
3. Faye-Petersen OM, Heller DS, Joshi VV. Lesions of the placenta as a whole or of the placental disk. In: Faye-Petersen OM, Heller DS, Joshi VV, eds. Handbook of placental pathology. 2nd ed. Abingdon, Oxford: Taylor & Francis; 2006:79-124.
4. Fox H, Sebire NJ. Macroscopic abnormalities of the placenta. In: Fox H, Sebire NJ, eds. Pathology of the placenta. 3rd ed. China: Elsevier; 2007;95-146.
5. Benirschke K, Burton GJ, Baergen RN. Nonvillous parts and trophoblast invasion. In: Benirschke K, Burton GJ, Baergen RN, eds. Pathology of human placenta. 6th ed. New York (NY): Springer; 2012:157-240.
6. Naeye RL. Maternal floor infarction. Hum Pathol 1985;16:823-8.
7. Andres RL, Kuyper W, Resnik R, et al. The association of maternal floor infarction of the placenta with adverse perinatal outcome. Am J Obstet Gynecol 1990;163:935-8.
8. Bane AL, Gillan JE. Massive perivillous fibrinoid causing recurrent placental failure. BJOG 2003;110:292-5.
9. Bendon RW, Hommel AB. Maternal floor infarction in autoimmune disease: two cases. Pediatr Pathol Lab Med 1996;16:293-7.
10. Mandsager NT, Bendon R, Mostello D, et al. Maternal floor infarction of the placenta: prenatal diagnosis and clinical significance. Obstet Gynecol 1994;83:750-4.
11. Nickel RE. Maternal floor infarction: an unusual cause of intrauterine growth retardation. Am J Dis Child 1988;142:1270-1.
12. Redline RW, Jiang JG, Shah D. Discordancy for maternal floor infarction in dizygotic twin placentas. Hum Pathol 2003;34:822-4.
13. Sebire NJ, Backos M, El Gaddal S, et al. Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients. Obstet Gynecol 2003;101:258-63.
14. Sebire NJ, Backos M, Goldin RD, et al. Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome. BJOG 2002;109:570-3.
15. Vernof KK, Benirschke K, Kephart GM, et al. Maternal floor infarction: relationship to X cells, major basic protein, and adverse perinatal outcome. Am J Obstet Gynecol 1992;167:1355-63.
16. Clewell WH, Manchester DK. Recurrent maternal floor infarction: a preventable cause of fetal death. Am J Obstet Gynecol 1983;147: 346-7.
17. Al-Adnani M, Kiho L, Scheimberg I. Recurrent placental massive perivillous fibrin deposition associated with polymyositis: a case report and review of the literature. Pediatr Dev Pathol 2008;11: 226-9.
18. Hung NA, Jackson C, Nicholson M, et al. Pregnancy-related polymyositis and massive perivillous fibrin deposition in the placenta: are they pathogenetically related? Arthritis Rheum 2006; 55:154-6.
19. Whitten AE, Romero R, Korzeniewski SJ, et al. Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol 2013;208:310.e1-11.
20. Chang P, Millar D, Tsang P, et al. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report. Am J Perinatol 2006;23: 125-9.
21. Hutton B, Sharma R, Fergusson D, et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG 2007;114:134-42.
22. Stephenson MD, Kutteh WH, Purkiss S, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod 2010;25:2203-9.
23. Fox KA, Longo M, Tamayo E, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fmslike tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol 2011;205:366.e1-5.
24. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011;108:1451-5.
25. Saad AF, Kechichian T, Yin H, et al. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci 2014;21:138-45.
26. Costantine MM, Tamayo E, Lu F, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fmslike tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 2010; 116:114-20.
27. Romero R, Whitten A, Korzeniewski SJ, et al. Maternal floor infarction/massive perivillous fibrin deposition: a manifestation of maternal antifetal rejection? Am J Reprod Immunol 2013;70: 285-98.
28. Redline RW, Heller D, Keating S, et al. Placental diagnostic criteria and clinical correlation-a workshop report. Placenta 2005;26: S114-17.
29. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350: 672-83.
30. Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonat Med 2005;17:3-18.
31. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
32. Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137-42.
33. Stepan H, Unversucht A, Wessel N, et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818-24.
34. Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonat Med 2008;21:279-87.
35. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonat Med 2008;21:9-23.
36. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonat Med 2009;22:1021-38.
37. Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One 2010;5:e13263.
38. Soto E, Romero R, Kusanovic JP, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonat Med 2012;25: 498-507.
39. McElrath TF, Lim KH, Pare E, et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012;207:407 e401-7.
40. Myatt L, Clifton RG, Roberts JM, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG 2013;120:1183-91.
41. Myers JE, Kenny LC, McCowan LM, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013; 120:1215-23.
42. Moore Simas TA, Crawford SL, Bathgate S, et al. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. J Matern Fetal Neonat Med 2014;27:1038-48.
43. Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonat Med 2008;21:25-40.
44. Asvold BO, Vatten LJ, Romundstad PR, et al. Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol 2011;173:630-9.
45. Alahakoon TI, Zhang W, Trudinger BJ, et al. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro-and anti-angiogenic profiles. J Matern Fetal Neonat Med 2014;27:1854-9.
46. Chaiworapongsa T, Romero R, Tarca A, et al. A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. J Matern Fetal Neonat Med 2009;22: 1122-39.
47. Romero R, Chaiworapongsa T, Erez O, et al. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonat Med 2010;23:1384-99.
48. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013;208:287.e1-15.
49. Lee J, Romero R, Xu Y, et al. Detection of anti-HLA antibodies in maternal blood in the second trimester to identify patients at risk of antibody-mediated maternal anti-fetal rejection and spontaneous preterm delivery. Am J Reprod Immunol 2013;70: 162-75.
50. Lee J, Romero R, Dong Z, et al. Unexplained fetal death has a biological signature of maternal anti-fetal rejection: chronic chorioamnionitis and alloimmune anti-human leucocyte antigen antibodies. Histopathology 2011;59:928-38.
51. Lee J, Romero R, Xu Y, et al. Maternal HLA panel-reactive antibodies in early gestation positively correlate with chronic chorioamnionitis: evidence in support of the chronic nature of maternal anti-fetal rejection. Am J Reprod Immunol 2011;66: 510-26.
52. Lee J, Romero R, Xu Y, et al. A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4d. PLoS One 2011; 6:e16806.
53. Kim MJ, Romero R, Kim CJ, et al. Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graftversus-host disease. J Immunol 2009;182:3919-27.
54. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13:176-89.
55. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-8.
56. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011;365:318-26.
57. Mak A, Cheung MW, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010;49:281-8.
58. Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol 2012;67:296-304.
59. Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet 2006;23:1-13.
60. Carp HJ, Sapir T, Shoenfeld Y. Intravenous immunoglobulin and recurrent pregnancy loss. Clin Rev Allergy Immunol 2005;29: 327-32.
61. Triolo G, Ferrante A, Accardo-Palumbo A, et al. IVIG in APS pregnancy. Lupus 2004;13:731-5.
62. Sirtori CR. The pharmacology of statins. Pharmacol Res 2014;88: 3-11.
63. Martin SS, Abd TT, Jones SR, et al. 2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better. J Am Coll Cardiol 2014;63:2674-8.
64. Bauer AJ, Banek CT, Needham K, et al. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension 2013;61:1103-10.
65. Frick M, Dulak J, Cisowski J, et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 2003;170:229-36.
66. Ahmed A, Cudmore MJ. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? Biochem Soc Trans 2009;37: 1237-42.
67. Hsu M, Muchova L, Morioka I, et al. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun 2006;343:738-44.
68. Ramma W, Ahmed A. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol 2014;101-102:153-60.
69. Zhao H, Azuma J, Kalish F, et al. Maternal heme oxygenase 1 regulates placental vasculature development via angiogenic factors in mice A deficiency in haem oxygenase-1 induces foetal growth restriction by placental vasculature defects. Biol Reprod 2011;85: 1005-12.
70. Wong RJ, Zhao H, Stevenson DK. A deficiency in haem oxygenase-1 induces foetal growth restriction by placental vasculature defects. Acta Paediatr 2012;101:827-34.
71. Melo AC, Valenca SS, Gitirana LB, et al. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury. Int Immunopharmacol 2013;17:57-64.
72. Ahmed A, Singh J, Khan Y, et al. A new mouse model to explore therapies for preeclampsia. PLoS One 2010;5:e13663.
73. Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J Reprod Immunol 2009;82:126-31.
74. Redecha P, van Rooijen N, Torry D, et al. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009;113:4101-9.
75. Elahi MM, Cagampang FR, Anthony FW, et al. Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring. Hypertension 2008;51:939-44.
76. Elahi MM, Cagampang FR, Ohri SK, et al. Long-term statin administration to dams on high-fat diet protects not only them but also their offspring from cardiovascular risk. Ann Nutr Metab 2013; 62:250-6.
77. McDonnold M, Tamayo E, Kechichian T, et al. The effect of prenatal pravastatin treatment on altered fetal programming of cardiovascular function in a preeclampsia-like murine model (Abstract 46). Am J Obstet Gynecol 2013;208(Suppl):S46.
78. McDonnold M, Tamayo E, Kechichian T, et al. The effect of prenatal pravastatin treatment on altered fetal programming of postnatal growth and metabolic function in a preeclampsia-like murine model. Am J Obstet Gynecol 2014;210:542.e1-7.
79. Saad A, Kechichian T, McDonnold M, et al. Mechanisms of fetal programming of adverse metabollic profile and its prevention by pravastatin in preeclampsia-like murine model. Am J Obstet Gynecol 2014;210(Suppl):S157.
80. Carver AR, Andrikopoulou M, Lei J, et al. Maternal pravastatin prevents altered fetal brain development in a preeclamptic CD-1 mouse model. PLoS One 2014;9:e100873.
81. Carver A, Tamayo E, Gamble P, et al. Maternal pravastatin therapy prevents altered brain development of the offspring in a murine model of preeclampsia (Abstract 37). Am J Obstet Gynecol 2014;210(Suppl):S25.
82. Carver AR, Tamayo E, Perez-Polo JR, et al. The effect of maternal pravastatin therapy on adverse sensorimotor outcomes of the offspring in a murine model of preeclampsia. Int J Dev Neurosci 2014;33:33-40.
83. Kane AD, Herrera EA, Hansell JA, et al. Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability. J Physiol 2012;590:323-34.
84. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
85. Bujold E, Romero R, Chaiworapongsa T, et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonat Med 2005;18:9-16.
86. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008;93:260-6.
87. Tannetta DS, Dragovic RA, Gardiner C, et al. Characterisation of syncytiotrophoblast vesicles in normal pregnancy and preeclampsia: expression of Flt-1 and endoglin. PLoS One 2013; 8:e56754.
88. Li H, Gu B, Zhang Y, et al. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005;26: 210-17.
89. Zhao S, Gu Y, Fan R, et al. Proteases and sFlt-1 release in the human placenta. Placenta 2010;31:512-18.
90. Cooper MK, Wassif CA, Krakowiak PA, et al. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 2003;33:508-13.
91. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004;131: 287-98.
92. Kusters DM, Hassani Lahsinoui H, van de Post JA, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther 2012;10:363-78.
93. Manson JM, Freyssinges C, Ducrocq MB, et al. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996;10:439-46.
94. Pollack PS, Shields KE, Burnett DM, et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005;73:888-96.
95. Lefkou E, Mamopoulos A, Fragakis N, et al. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension 2014;63:e118-19.
96. Costantine MM, Cleary K, Eunice Kennedy Shriver National Institute of Child H, et al. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013; 121:349-53.
97. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997; 33:328-343.
98. Zarek J, DeGorter MK, Lubetsky A, et al. The transfer of pravastatin in the dually perfused human placenta. Placenta 2013; 34:719-21.
99. Nanovskaya TN, Patrikeeva SL, Paul J, et al. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 2013;209:373.e1-5.
100. Onda K, Hannan N, Beard S, et al. Proton pump inhibitors for treatment of preeclampsia Abstract [6-OR]. Pregnancy Hypertens 2015;5:3.
101. Onda K, Hannan N, Beard S, et al. Proton pump inhibitors decrease sFlt-1 and soluble endoglin production, quench endothelial dysfunction and promote vasodilation in whole blood vessels: a candidate therapeutic for severe preeclampsia (Abstract F-288). Reprod Sci 2015;22(Suppl. 1):294A.